# US 2020/0261418 A1 · Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0261418 A1
- Document ID: US20200261418A1
- Status: Published application
- Kind: A1
- Application number: 16/644,751
- Filed: 2018-09-07
- Published: 2020-08-20
- Earliest claimed: 2017-09-08
- Assignees: 4Sc AG
- Applicants: 4Sc AG
- Inventors: Susanne DANHAUSER-RIEDL; Frank HERMANN; Roland BAUMGARTNER; Svetlana HAMM; Rene BARTZ
- Web page: https://patentgrep.com/patent/US20200261418A1

## CPC

- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention relates to methods, compositions and uses for the of treatment of cancer comprising the administration of an HDAC inhibitor as defined herein for the treatment of cancer in combination with at least one immune checkpoint modulator as defined herein.

## Claims

### Claim 1

A method for the treatment of cancer, comprising administering to a subject in need thereof an effective amount of an HDAC inhibitor of formula I in combination with at least one immune checkpoint modulator,
in which
R1, R4 and R5 are independently hydrogen, 1-4C-alkyl, halogen, or 1-4C-alkoxy,
R2 and R3 are independently hydrogen or 1-4C-alkyl,
R6 is -T1-Q1, in which T1 is a bond or 1-4C-alkylene,
either Q1 is substituted by R61 and/or R62, and is Aa1, Hh1, Ha1, Ha2, Ha3, Ha4 or Ah1, or Q1 is unsubstituted, and is Ha2, Ha3 or Ha4,
in which
R61 is 1-4C-alkyl, phenyl-1-4C-alkyl, 1-4C-alkoxy, hydroxyl, trifluoromethyl, cyano, halogen, completely fluorine-substituted 1-4C-alkoxy or 1-4C-alkoxy wherein more than half of the hydrogen atoms are replaced by fluorine atoms, hydroxy-1-4C-alkyl, 1-4C-alkoxy-1-4C-alkyl, 1-4C-alkylsulphonylamino, tolylsulphonylamino, phenylsulphonylamino, 1-4C-alkylcarbonylamino, carbamoyl, sulphamoyl, mono- or di-1-4C-alkylaminocarbonyl, mono- or di-1-4C-alkylaminosulphonyl, -T2-N(R611)R612, —U-T3-N(R613)R614, -T4-Het3, or —V-T5-Het4, in which
T2 is a bond or 1-4C-alkylene,
R611 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl, 1-4C-alkoxy-2-4C-alkyl, 1-4C-alkylcarbonyl, or 1-4C-alkylsulphonyl,
R612 is hydrogen or 1-4C-alkyl,
or R611 and R612 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het1, in which Het1 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, or 4N-(1-4C-alkyl)-piperazino,
U is —O— (oxygen) or —C(O)NH—,
T3 is 2-4C-alkylene,
R613 is hydrogen, 1-4C-alkyl, 3-7C-cycloalkyl, 3-7C-cycloalkylmethyl, hydroxy-2-4C-alkyl or 1-4C-alkoxy-2-4C-alkyl, 1-4C-alkylcarbonyl, or 1-4C-alkylsulphonyl R614 is hydrogen or 1-4C-alkyl,
or R613 and R614 together and with inclusion of the nitrogen atom, to which they are bonded, form a heterocyclic ring Het2, in which
Het2 is morpholino, thiomorpholino, S-oxo-thiomorpholino, S,S-dioxo-thiomorpholino, piperidino, pyrrolidino, piperazino, or 4N-(1-4C-alkyl)-piperazino,
T4 is a bond or 1-4C-alkylene,
Het3 is 1N-(1-4C-alkyl)-piperidinyl or 1N-(1-4C-alkyl)-pyrrolidinyl,
V is —O— (oxygen) or —C(O)NH—,
T5 is a bond or 1-4C-alkylene,
Het4 is 1N-(1-4C-alkyl)-piperidinyl or 1N-(1-4C-alkyl)-pyrrolidinyl,
R62 is 1-4C-alkyl, 1-4C-alkoxy or halogen,
Aa1 is a bisaryl radical made up of two aryl groups,
which are selected independently from a group consisting of phenyl and naphthyl, and which are linked together via a single bond,
Hh1 is a bisheteroaryl radical made up of two heteroaryl groups,
which are selected independently from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and
which are linked together via a single bond,
Ah1 is an arylheteroaryl radical made up of an aryl group selected from a group consisting of phenyl and naphthyl, and a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, whereby said aryl and heteroaryl groups are linked together via a single bond, and whereby Ah1 is bonded via said heteroaryl moiety to the parent molecular group,
Ha1 is a heteroarylaryl radical made up of a heteroaryl group selected from a group consisting of monocyclic 5- or 6-membered heteroaryl radicals comprising one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, and whereby Ha1 is bonded via said aryl moiety to the to the parent molecular group,
Ha2 is a heteroarylaryl radical made up of a heteroaryl group selected from a group consisting of fused bicyclic 9- or 10-membered heteroaryl radicals comprising one, two or three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, and whereby Ha2 is bonded via said aryl moiety to the parent molecular group,
Ha3 is a heteroarylaryl radical made up of a heteroaryl group selected from a group consisting of monocyclic 5-membered heteroaryl radicals comprising three or four heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, and whereby Ha3 is bonded via said aryl moiety to the to the parent molecular group,
Ha4 is a heteroarylaryl radical made up of a heteroaryl group selected from a group consisting of partially saturated fused bicyclic 9- or 10-membered heteroaryl radicals comprising a heteroatom-free benzene ring and one or two heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur, and an aryl group selected from a group consisting of phenyl and naphthyl, whereby said heteroaryl and aryl groups are linked together via a single bond, and whereby Ha4 is bonded via said aryl moiety to the to the parent molecular group,
R7 is hydroxyl, or Cyc1, in which Cyc1 is a ring system of formula Ia
in which
A and B are C (carbon),
R71 and R72 are independently hydrogen, halogen, 1-4C-alkyl, or 1-4C-alkoxy,
M with inclusion of A and B is either a ring Ar2 or a ring Har2, in which Ar2 is a benzene ring, Har2 is a monocyclic 5- or 6-membered unsaturated heteroaromatic ring comprising one to three heteroatoms, each of which is selected from the group consisting of nitrogen, oxygen and sulfur.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the HDAC inhibitor is (E)-N-(2-aminophenyl)-3-(1-((4-(1-methyl-1H-pyrazol-4-yl)phenyl) sulfonyl)-1H-pyrrol-3-yl)acrylamide (also known as 4SC-202).

### Claim 3 (depends on 2)

The method according to claim 2, wherein (E)-N-(2-aminophenyl)-3-(1-((4-(1-methyl-1H-pyrazol-4-yl)phenyl) sulfonyl)-1H-pyrrol-3-yl)acrylamide is administered in a dose of 150 to 250 mg/day, wherein the aforementioned daily doses are optionally administered in two portions, twice daily.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the at least one immune checkpoint modulator is selected from the group consisting of a) inhibitors of anti-inflammatory immune checkpoints including PD-1, CTLA-4, A2AR, B7-H3 (also known as CD276), B7-H4 (also known as VTCN1), BTLA, IDO, KIR, LAG3, TIM-3, VISTA (V-domain Ig suppressor of T cell activation) and their respective ligands including PD-L1, PD-L2, and galectin), and b) agonists of pro-inflammatory immune checkpoints including CD27, CD40, OX40, GITR, CD137, CD28, ICOS, and their respective ligands, including CD70 CD80, CD86, CD40L, CD137 ligand, OX40L, GITR ligand and ICOSL.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the at least one immune checkpoint modulator is selected from the group consisting of Ipilimumab, pembrolizumab, avelumab, nivolumab, durvalumab, tremelimumab, BCD-100 (Biocad), PDR-001 (Novartis), REGN-2810 (Regeneron), Camrelizumab (Shanghai Hengrui), SHR-1210 (Incyte), AGEN-2034 (Agenus), BGBA-317 (BeiGene), BMS-936559 (ViiV Healthcare), CX-072 (CytomX), CX-188 (CytomX), GNS-1480 (Genosco/Yuhan), IBI-308 (Eli Lilly/Innovent), JNJ-63723283 (J&J), JS-001 (Shanghai Junshi), MEDI-0680 (MedImmune), AMP-224 (MedImmune), BGB-A317 (BeiGene/Celgene), BI-754091 (Boehringer), CA-170 (Curis/Aurigene), CBT-501 (CBT Pharma), Genolimzunab (Genor), CBT-502 (CBT Pharma), FAZ-053 (Novartis), GLS-010 (Harbin/Wuxi/Arcus), AB122 (Harbin/Wuxi/Arcus), LY-3300054 (Eli Lilly), KN-035 (AlphaMab), M-7824 (Merck KGaA), MAG-012 (MacroGenics), MGD-013 (MacroGenics), PF-06801591 (Pfizer), SHR-1316 (Jiangsu Hengrui), TSR-042 (Tesaro), CS-1001 (CStone Pharma), HLX-10 (Shanghai Henlius), MCLA-145 (Merus/Incyte), AM-0001 (ARMO Bio), AVA-004 (Avacta), STI-al014 (Lee's Pharma/Sorrento), hAb-21 (Suzhou Stainwei), AK103 (Akeso Bio), AK104 (Akeso Bio), AK105 (Akeso Bio), AK106 (Akeso Bio), AK112 (Akeso Bio), BBI (Boston Biomedicals), BH-2922 (Beijing Hanmi), BH-2941 (Beijing Hanmi), BH 2950 (Beijing Hanmi), CA-327 (Curis/Aurigene), CBA-0710 (Sorrento), CK-301 (TG therapeutic), ENUM-244C8 (Enumeral), FS-118 (F-star Alpha/Merck KGaA), HTI-1316 (Hengrui Therapeutics), IKT-201 (Icell Kealex), IKT-202 (Icell Kealex), vaccinia virus expressing checkpoint inhibitor (Icell Kealex), JS-003 (Shanghai Junshi), JTX-4014 (Jounce/Celgene), KD033 (Kadmon/Jinghua Pharma), KY-1003 (Kymab), MCLA-134 (Merus), MSB-2311 (MABSPACE Bio), PRS-332 (Pieris/Servier), RXI-762 (Rxi Pharmaceuticals), SN-PD07 (Synovel), SN-PDL01 (Synovel), STI-A1110 (Sorrento/Servier), XmAb20717 (Xencor), AT16201 (AIMM), HLX-20 (Shanghai Henlius), IMM-1802 (ImmuneOnco Biopharma Shanghai), IMM-25 (ImmuneOnco Biopharma Shanghai), IMM-2502 (ImmuneOnco Biopharma Shanghai), IMM-2503 (ImmuneOnco Biopharma Shanghai), IMM-2504 (ImmuneOnco Biopharma Shanghai), CDX-1127 (Celldex Therapeutics NKTR-214 (Nektar Therapeutics), MEDI0562 (AstraZeneca), MEDI6469 (AstraZeneca), MEDI6383(AstraZeneca), MGA271 (MacroGenics), Lirilumab, and atezolizumab.

### Claim 6 (depends on 5)

The method according to claim 5, wherein pembrolizumab is administered in a dose of 2 mg/kg, or in a dose of 200 mg, nivolumab is administered in a dose of 3 mg/kg, or in a dose of 240 mg or in a dose of 480 mg, ipilimumab is administered in a dose of 3 mg/kg or in a dose of 10 mg/kg, avelumab is administered in a dose of 10 mg/kg, atezolizumab is administered in a dose of 1200 mg, durvalumab is administered in a dose of 1500 mg, tremelimumab is administered in a dose of 1 mg/kg, in a dose of 75 mg.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the HDAC inhibitor is administered on days 1 to 14, or on days 1, 3, 5, 7, and 9, and the at least one immune checkpoint modulator is administered on day 1 in a 21-day treatment cycle, or wherein the HDAC inhibitor is administered on days 1 to 7, or on days 1, 3, and 5, and the at least one immune checkpoint modulator is administered on day 1 in a 14-day treatment cycle.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the treatment comprises a first treatment cycle wherein only the HDAC inhibitor is administered prior to administering the HDAC inhibitor and the immune checkpoint modulator.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the treatment comprises administering the HDAC inhibitor to the patient having said cancer in the non-fasted state.

### Claim 10 (depends on 1)

The method according to claim 1, wherein said cancer is a solid tumor.

### Claim 11 (depends on 1)

The method according to claim 1, wherein said cancer is selected from the group consisting of melanoma including ocular, uveal and skin melanoma, head and neck, renal, NSCLC, microsatellite-instable carcinoma including lynch syndrome including gastroesophageal and colorectal, urothelial carcinoma including bladder, merkel cell carcinoma, hodgkin lymphoma, gastric, oesophageal, non-hodgkin lymphoma, SCLC, sarkoma, mesothelioma, glioblastoma, microsatellite stable including gastroesophageal and colorectal, pancreas, HCC, prostata, basal cell carcinoma, CTCL, and squamous cell carcinoma.

### Claim 12 (depends on 1)

The method according to claim 1, wherein said cancer is a refractory, non-responding or relapsed to immune checkpoint modulator therapy.

### Claim 13 (depends on 1)

The method according to claim 1, wherein the patient having said cancer has received at least one prior systemic treatment against said cancer.

### Claim 14 (depends on 1)

The method according to claim 1, wherein said cancer is resistant to immune checkpoint modulator therapy.
